您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 首席执行官
所属公司: 邦耀生物
个人简介:
郑彪博士毕业于浙江大学医学院医学系;获上海复旦大学医学院免疫学硕士及伦敦大学 (King’s College, University of London) 免疫学博士学位。曾在美国马里兰大学医学院 (University of Maryland School of Medicine) 及杜克大学医学中心 (Duke University Medical Center) 任教。随后任职于美国贝勒医学院 (Baylor College of Medicine), 为该校病理和免疫系终身教授。在葛兰索史克 (GlaxoSmithKline) 研发中心负责免疫学研究工作。曾任美国强生公司(Janssen Pharmaceuticals, Johnson & Johnson) 全球副总裁, 负责亚太地区免疫领域创新药物研发,包括免疫调节机制、肿瘤免疫、及自身免疫性疾病。郑彪博士现任邦耀生物首席执行官。郑彪教授学术著作丰厚,其中多篇发表在Nature和Science等世界顶尖杂志上。在马里兰大学、杜克大学及贝勒医学院工作期间获得多项重大科研基金,包括美国NIH科研基金、白血病与淋巴瘤协会基金、美国关节炎基金会、美国心脏研究协会基金、美国衰老研究联盟基金等。在药物研发方面,从新药筛选、靶点研究、疾病模型、临床前及临床试验等方面积累了重要的经验,对新药开发全过程有深刻的认识。在打造小分子药,大分子抗体药,细胞治疗管线均有丰富的经验。Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng worked for GlaxoSmithKline R&D Center as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Executive Officer at BRL Medicine.Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 副总裁
所属公司: 苏州开拓药业
个人简介:
许若博士本科就读于北京大学化学系,之后获美国哥伦比亚大学博士学位。从1998年开始,许博士先后在先灵堡雅、默克、API Inc.等美国大小制药企业的工作20多年,在药物化学,工艺化学,原料药的cGMP制造,CMC文件准备和提交等领域积累了丰富的经验。许博士于2019年4月回国加入开拓药业股份有限公司,担任化学副总裁职务。全面负责公司的药物化学的研发和原料药的生产工作。Dr. Xu received his bachelor's degree in chemistry from Peking University and his Ph.D. from Columbia University. After his academic training, Dr. Xu has worked in pharmaceutical industry for more than 20 years, including Schering-Plough, Merck, API Inc. etc. in the United States. During this time, he accumulated rich experience in medicinal chemistry, process chemistry, cGMP manufacturing of APIs, CMC document preparation and submission, etc. Dr. Xu returned to China in April 2019 and joined Kintor Pharma as Vice President of Chemistry. He is responsible for the medicinal chemistry research and the production of APIs of the company.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 创始人、董事长兼总经理
所属公司: 宜明昂科生物医药技术(上海)股份有限公司
个人简介:
田文志博士,上海市“千人计划”专家、浦东新区“百人计划”专家、科技部火炬中心科技创新创业人才、复旦大学药学院兼职教授,现任宜明昂科生物医药技术(上海)股份有限公司董事长兼总经理。于1995年10月至2011年4月先后在瑞典、美国留学及工作,主要从事肿瘤免疫学及抗肿瘤抗体药物开发研究。累计发表学术论文30余篇,克隆新基因7个,参编英文专著一部,申请新药发明专利40余项,获得授权13项。2011年4月辞职回国,先后创办了华博生物医药技术(上海)有限公司、宜明昂科生物医药技术(上海)股份有限公司及宜明探科生物医药技术(上海)有限公司。回国12年以来,已将 8个新药项目开发至临床试验阶段,其中7项已开展临床试验。Dr. Wenzhi Tian is the founder and Chairman of IImmuneOnco Biopharmaceuticals (Shanghai) Inc., a clinical stage biotech company headquartered in Shanghai, China, with primary focus on research and development of tumor immunotherapeutic drugs including checkpoint modulators and target-activated NK (TANKTM) products. Prior to ImmuneOnco Biopharma, Dr. Tian worked as Chief Executive Officer at Huabo Biopharm from June of 2011 to April of 2015. During that period, Dr. Tian advanced two large molecule programs to the clinical stage. Prior to moving back to China, Dr. Tian worked as Principal Research Scientist at ImClone Systems from January of 2006 to April of 2011. Dr. Tian graduated from Henan Medical University (Now Zhengzhou University School of Medicine) and did his postdoctoral training at North Shore University Hospital, NYU School of Medicine. He was appointed a Senior Research Associate at Weill Medical College of Cornell University thereafter.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 执行董事、首席执行官
所属公司: 苏州创胜医药集团有限公司
个人简介:
钱雪明博士是创胜集团医药有限公司(下称创胜集团)的首席执行官。创胜集团是一家具备生物药发现、研发、工艺开发和生产全流程整合能力的临床阶段的生物制药公司。2021年9月29日,创胜集团在香港联合交易所主板上市,股票代码:06628。钱雪明博士毕业于复旦大学生物物理学系 (1985 – 1990),并分别在哥伦比亚大学 (Columbia University, 1990 – 1992) 和奥尔巴尼医学中心 (Albany Medical Center, 1995 – 1997) 获得神经学与生理学硕士学位和神经学与药理学博士学位。钱雪明博士拥有 20 年的生物制药行业经验。在创立创胜集团之前,钱博士于 2010-2013 年间任盛诺基医药集团 (Shenogen Pharma Group) 研发总裁和董事会成员。1997-2010 间任职于美国安进公司,专注于抗体新药的开发。钱博士是十多个创新药物专利申请的发明人,也是国际抗体协会会员、国际肾病协会会员、新药创始人俱乐部、创新生物社和 BayHelix 百华协会会员,获得了国家级高层次人才、苏州工业园区科技领军人才和苏州市姑苏创新创业领军人才等支持。Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics. Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR, ASN and Antibody Society.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务